Crispr Therapeutics AG (CRSP) Stock Forecast & Price Target
Crispr Therapeutics AG · NASDAQ
$54.78-1.01 (-1.81%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 13 firms covering Crispr Therapeutics AG, 9 rate it Buy or better, 4 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $44.00 to $110.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $72.92 sits 33% above the current $54.78. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.16 next quarter toward $-3.50 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS13 ratings
Moderate Buy
Strong Buy00%
Buy969%
Hold431%
Sell00%
Strong Sell00%
Based on 13 analysts giving stock ratings to Crispr Therapeutics AG.
As of Sep, 8 of 12 firms rate CRSP a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CRSP EPS & revenue forecast
EPS · NEXT QUARTER
$-1.16
Range $-2.02 – $-0.51 · 17 analysts · -16% YoY
Next period, 17 analysts expect Crispr Therapeutics AG to earn $-1.16 a share (range $-2.02 – $-0.51), versus $-1.37 a year earlier. Full-year consensus is $-4.45, growing to $-3.50 the year after.
REVENUE · NEXT QUARTER
$16.4M
Range $0 – $75.4M · 17 analysts · +1793% YoY
Revenue is expected to reach $16.4M (range $0 – $75.4M), +1792.9% year-over-year. Full-year consensus is $40.8M, rising to $156.6M next year.
Top analysts covering Crispr Therapeutics AG
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CRSP.
#1
Luca Issi
RBC Capital · Rank #1
Hold
$50.00-8.7% to target
Overall win rate
55%
+ Follow
#2
Silvan Tuerkcan
JMP Securities · Rank #26
Buy
$80.00+46.0% to target
Overall win rate
53%
+ Follow
#3
Geulah Livshits
Chardan Capital · Rank #85
Buy
$76.00+38.7% to target
Overall win rate
46%
+ Follow
#4
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Buy
$80.00+46.0% to target
Overall win rate
34%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$88.00+60.6% to target
Overall win rate
41%
+ Follow
CRSP stock forecast FAQ
What is CRSP's average 12-month price target?+
The 13 analysts with a live target average $72.92 for Crispr Therapeutics AG over the next 12 months, ranging from a $110.00 high to a $44.00 low.
Is CRSP stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 13 analyst ratings, 9 are Buy or Strong Buy, 4 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CRSP?+
The Street-high target is $110.00 (Piper Sandler), and the Street-low is $44.00 (Baird). The average of all 13 active targets is $72.92.
How many Wall Street analysts cover CRSP?+
13 analysts have an active rating on Crispr Therapeutics AG, and 13 firms carry a live 12-month price target.
Who is the most accurate analyst covering CRSP?+
Among analysts who currently cover CRSP, Luca Issi of RBC Capital has the strongest overall Quantellect track record (Rank #1). Their current call is Hold with a $50.00 target.
What is Crispr Therapeutics AG's projected EPS for next quarter?+
The consensus estimate is $-1.16 per share (range $-2.02 – $-0.51) across 17 analysts. Full-year EPS is projected at $-4.45, rising to $-3.50 the following year.
How much revenue is Crispr Therapeutics AG expected to report next quarter?+
Consensus revenue is $16.4M (range $0 – $75.4M). Full-year revenue is projected at $40.8M, growing to $156.6M next year.
Have analysts been upgrading or downgrading CRSP lately?+
As of Sep, 8 of 12 firms rate CRSP a Buy (4 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CRSP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
